The acquisition will add novel scientific platform and manufacturing expertise to Nano Vivere’s research and operational capabilities.

Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that Nano Vivere and global lead in cellular immunotherapy company will sign a definitive merger agreement in which Nano Vivere has agreed to acquire the company. The name of the..

View more at https://www.1888pressrelease.com/nano-vivere-to-acquire-global-leadership-in-cellular-immunot-pr-639963.html